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Objectives: Patients with RA have a higher risk of ischemic cardiac events com-
pared with the general population. This would be explained not only by the greater 
presence of traditional risk factors, but also by the systemic inflammatory nature 
of the disease. Compare self-reported prevalence of risk factors in rheumatoid 
patients with prevalence data from the brazilian general population. MethOds: 
Cross-sectional study between July and November 2014 including 183 patients with 
rheumatoid arthritis of both sexes, aged 20 years or older, in primary or secondary 
care units of the city of Blumenau, southern Brazil. Data collection was conducted 
through structured personal interview and, if needed, later complemented by phone. 
The national survey Vigitel 2012 was used to collect data from brazilian general 
population. Results: The target population consisted of 183 patients, 153 (83.6%) 
were female, mean age of 56.9 years and mean duration of disease of 12.1 years. The 
prevalence of self-reported comorbidities of the target population when compared 
with general population prevalence was respectively: hypertension 44.8% versus 
28.3%, diabetes mellitus 9.2% versus 12.5%, dyslipidemia 22.9% versus 16.5%, over-
weight 41.5% versus 35.8% and obesity 18.5% versus 19.1%, prior smoking 45.9% ver-
sus 23.4%, current smoking 8.7% versus 12.8%, physical inactivity 65% versus 14.2%. 
Positive family history for cardiovascular disease was observed in 42% of rheumatoid 
patients, that shows mean body mass index of 26.3 kg/m2. cOnclusiOns: The 
study result shows that the self-reported prevalence of traditional risk factors for 
ischemic heart disease in patients with rheumatoid arthritis in Blumenau is higher 
than the national prevalence of hypertension, dyslipidemia, overweight, previous 
smoking and physical inactivity. By contrast, the prevalence is lower for diabetes 
mellitus and current smoking.
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Objectives: To examine the resource utilization and direct costs of care in severe 
spondyloarthritis (SpA) patients based on a national representative claims data-
base. MethOds: The EGB Database is a national representative random sample of 
1 out of every 97 individuals covered by the main French public health insurance 
schemes, listing all healthcare consumption and allowing identification of beneficiar-
ies eligible for full health insurance coverage due to severe conditions. The annual 
economic burden related to severe SpA was estimated by comparing direct medical 
expenses (outpatient care and hospitalization costs) in the SpA adult (≥ 18 years) 
population to a control group (i.e. patients not in “Affection de Longue Durée” for 
severe SpA in 2012) matched for age and sex, using non-parametric Mann-Whitney 
tests. Overall cost (healthcare utilization and associated costs) was assessed from 
the Health Insurance perspective for 2012. Results: Among 470,326 adults in the 
database, 827 patients presenting with severe SpA were identified, corresponding to 
a nationwide prevalent population estimate of 88,275 patients in France in 2012. High 
blood pressure, recurrent major depressive disorders and other comorbidities taken as 
a whole were significantly more frequent in severe SpA patients than controls (4.5% 
vs 1.8%, p< 0.0001; 3.1% vs 1.5%, p= 0.003 and 24.7% vs 18.8%, p= 0.0003, respectively). 
Annual medical costs per severe SpA patient were 3.5 times higher than that of 
controls (mean costs: € 6,122±8,179 vs € 1,682±5,769, p< 0.0001; median costs: € 2,519 
vs € 300). The main contributors to this incremental cost were (mean values): medica-
tions (+€ 2,390, 53.8%), hospitalization (+€ 1,038, 23.4%) and healthcare professional 
consultations (+€ 716.7, 16.2%). The annual economic burden related to severe SpA in 
France in 2012 is estimated around € 391M. cOnclusiOns: The burden of severe SpA 
is significant in France with regard to comorbidities and medical costs supported by 
the healthcare system, as identified in this representative database analysis.
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Objectives: The changes of vitamin D level influencing bone metabolism are sea-
sonal, the effect of seasons on femoral neck fracture healing is unknown. The aim of 
our study was to determine the effects of seasonal periodicity on incidence of oste-
onecrosis following primary osteosynthesis of femoral neck fractures in Hungarian 
elderly population. MethOds: This nationwide retrospective observational cohort 
study based on dataset of National Health Insurance Fund Administration. Patients 
over 60 years undergoing internal fixation after primary femoral neck fracture 
(ICD10-S7200) and were discharged in 2000 were identified. Inpatient cases devel-
oping osteonecrosis were registered during the 8 years follow-up. The following 
factors were evaluated: sex, age, type of fracture, season of surgical intervention, 
day of surgery, surgical delay and comorbidities. The effect of seasons on survival 
time was investigated by Kaplan–Meier analysis and log-rank test. The crude inci-
dence rate ratios of osteonecrosis were calculated for factors. The impact of risk 
factors on the hazard of osteonecrosis was estimated by Cox proportional hazard 
model. Results: 3312 patients fit the criteria. During the observation period 106 
osteonecrosis (3.2%) were identified, yielding an overall incidence 8.87 per 1000 
person-years. The crude incidence rates were 14.38, 8.57, 6.58, and 5.70 per 1000 
person-years in winter, spring, summer, and fall. No significant differences were 
found in survival with respect to season with Kaplan–Meier analysis (p= 0.173). 
data was collected via phone calls through a specific questionnaire answered by 
PM women aged ≥ 50 years old (yo) who were in the registry and contacted directly 
by SPR researchers. Results: We surveyed 1.587 PM women with a mean age of 
66.0 yo (SD= 9.2). 43% had PM osteoporosis, but only 38.4% of women had previous 
knowledge of it. Previous diagnosis was mostly done by primary care physicians 
(57.9%). Less than a tenth (9.1%) had osteoporosis treatment. The most common 
pharmaceutical treatment was oral bisphosphonates (19.8%), followed by stron-
tium ranelate (7.8%). 199 women (12.5%) had stopped osteoporosis treatment in the 
12-month period previous to the questionnaire. This decision was driven by patients 
(61.3%) followed by the physicians (36.2%) and self-reported reasons were economic, 
polymedication, efficacy, gastrointestinal adverse events and other safety concerns. 
Of special interest, gastrointestinal adverse events were self-reported by more than 
a third of those women ever treated for osteoporosis (36.1%). This led to more health-
care consumption and treatment changes. cOnclusiOns: In this report, using a 
large sample from a patient registry, we observed low rates of treatment and high 
levels of therapy discontinuation in Portugal. A further understanding of underlying 
reasons for under-treatment and non-persistence is crucial to attain better health 
outcomes in post-menopausal osteoporosis.
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Objectives: Osteoporosis and chronic inflammatory rheumatic diseases (CIRD), 
including rheumatoid arthritis (RA), psoriatic arthritis (PA) and ankylosing spon-
dylitis (AS), are major issues in rheumatology. In these two therapeutic areas, data 
are needed to describe burden of disease and clinical management. Our objective 
was to identify patients likely to have osteoporosis or CIRD within French claims 
database, before running analyses. MethOds: As there is no diagnosis code in the 
database, treatment pattern or medical resource utilization were used to identify 
patients. Patients with osteoporosis were identified using age (≥ 50), reimbursement 
of anti-osteoporotic agents (ATC codes), osteoporosis-related hospitalization, or 
Long Term Disease (LTD) status, based on ICD-10 codes. For CIRD, the study popula-
tion included 3 sub-groups: patients with RA, PA and AS. For AS, identification was 
based on hospitalizations and LTD status for ICD-10 codes M08.1, M08.8, M08.9, 
M45, and M46. Identification for RA was based on ICD-10 codes M05, M06, M08.0, 
M08.2, M08.4 and M13. Identification for PA was based on ICD-10 codes M07 and 
M09. Results: Identification criteria for osteoporosis allowed to identify 7,939 
patients, corresponding to 4.5% of the French population ≥ 50 years. This popula-
tion consists of 92% of women and mean age is 71.6 years. Identification criteria 
selected 2,070 for RA, 923 patients for SA, and 492 patients for RP, corresponding 
to 3,223 patients with CIRD disease (0.62% of French population) cOnclusiOns: 
4.5% of patients of the French population have osteoporosis based on our selection 
criteria; a majority are old women, in line with the literature. For CIRD, 3,223 patients 
were identified, which is also consistent with the literature. Next steps will include 
the description of treatment patterns and the burden of  disease.
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Objectives: In France, the ECLAIR non-interventional, multicenter study was 
initiated to follow up real-world, moderate-to-severe, active RA patients treated 
with certolizumab pegol (CZP), prospectively for up to 3 years. In 2003, prescrip-
tion of glucocorticoids (GCs) in French patients with active RA was evaluated,1 
showing that > 50% received GCs, although GC use has not been comprehensively 
studied to date.1The objective is to describe baseline characteristics of French 
RA patients starting CZP, such as disease and treatment history, and concomi-
tant medication. MethOds: The ECLAIR study, run by 170 rheumatologists and 
6 internal medicine specialists, was designed to be representative of the French 
RA population. Baseline data, collected from treating physicians and patients via 
questionnaires, included history of RA treatments and concomitant diseases and 
their treatments. Results: 791 patients were included: 790 were used for analysis, 
1 was excluded for lack of signed informed consent. Patient characteristics: mean 
(SD) age 55.0 (13.1); 78.7% female; RA duration 8.9 (9.1) years; 73.4% rheumatoid 
factor positive; DAS28(ESR) 4.9 (1.3); disease activity moderate for 50.1% and high 
for 41.1% of patients. Mean HAQ-DI total score: 1.28 (0.69). Concomitant diseases: 
23.2% (183/790) of patients had vascular disorders, 19.1% (151/790) metabolism and 
nutrition disorders and 17.5% (138/790) musculoskeletal and connective tissue dis-
orders. Concomitant treatments included NSAIDs in 35.2% of patients, steroids in 
51.4% of patients and cDMARDs in 64.6% of patients (MTX: 53.5%, leflunomide: 9.0%, 
hydroxychloroquine: 2.8%, sulfasalazine: 2.4%, azathioprine: 0.3%, thalidomide: 
0.1%). cOnclusiOns: ECLAIR is the first anti-TNF, prospective, real-world study 
conducted in France, providing insights into the population of RA patients treated 
with anti-TNF therapy such as CZP. Baseline data showed that half of patients on 
CZP received GCs, similar to previous reports in the French RA population.1Further 
targeted statistical analyses on ECLAIR data could clarify trends associated with 
concomitant medication. REFERENCES: 1. Saraux A. J Rheumatol 2006 Jul;33:1258-6
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